Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.

ABSTRACT:

Purpose

Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3. This phase III trial compared tivozanib with sorafenib as initial targeted therapy in patients with metastatic renal cell carcinoma (RCC).

Patients and methods

Patients with metastatic RCC, with a clear cell component, prior nephrectomy, measurable disease, and 0 or 1 prior therapies for metastatic RCC were randomly assigned to tivozanib or sorafenib. Prior VEGF-targeted therapy and mammalian target of rapamycin inhibitor were not permitted. The primary end point was progression-free survival (PFS) by independent review.

Results

A total of 517 patients were randomly assigned to tivozanib (n = 260) or sorafenib (n = 257). PFS was

SUBMITTER: Motzer RJ 

PROVIDER: S-EPMC5569677 | biostudies-literature | 2013 Oct

REPOSITORIES: biostudies-literature